What is he best known for?
The fields of study he is best known for:
- Immune system
- Cytokine
- Internal medicine
His primary scientific interests are in Chemokine, Immunology, Cytokine, Eotaxin and Chemokine receptor.
His studies deal with areas such as Synovitis, Molecular biology and Chemotaxis as well as Chemokine.
Mariagrazia Uguccioni regularly ties together related areas like Virology in his Immunology studies.
His research investigates the connection between Cytokine and topics such as Inflammation that intersect with problems in Pathology.
His Eotaxin research incorporates elements of Skin biopsy, CCR3, CCL5 and Allergy.
In his study, CCL27 is inextricably linked to CC chemokine receptors, which falls within the broad field of CCL13.
His most cited work include:
- Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. (787 citations)
- CCR5 is characteristic of Th1 lymphocytes (783 citations)
- Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release (456 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Immunology, Chemokine, Chemokine receptor, Cell biology and Pathology.
His research in Chemokine intersects with topics in Molecular biology, Chemotaxis and Monocyte.
Mariagrazia Uguccioni combines subjects such as Cancer research and HMGB1 with his study of Chemokine receptor.
His work deals with themes such as Chondrocyte and CXC chemokine receptors, which intersect with Cell biology.
His Pathology research focuses on CXCL13 and how it connects with Follicular dendritic cells.
His research investigates the connection with CCL21 and areas like CCL20 which intersect with concerns in CXCR5.
He most often published in these fields:
- Immunology (47.33%)
- Chemokine (48.85%)
- Chemokine receptor (37.40%)
What were the highlights of his more recent work (between 2017-2021)?
- Chemokine receptor (37.40%)
- Chemokine (48.85%)
- Inflammation (22.90%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Chemokine receptor, Chemokine, Inflammation, Cancer research and Signal transduction.
His research in Chemokine receptor focuses on subjects like HMGB1, which are connected to Biophysics.
Mariagrazia Uguccioni has researched Chemokine in several fields, including Chemotaxis, Homing and Cell biology.
Mariagrazia Uguccioni interconnects Extracellular and Tissue damage in the investigation of issues within Inflammation.
His Cancer research research includes elements of Cancer, Synovial membrane, CCR1, CCL20 and C-C chemokine receptor type 6.
His study in Signal transduction is interdisciplinary in nature, drawing from both Receptor, Cell migration, Neuroscience and Personalized therapy.
Between 2017 and 2021, his most popular works were:
- Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis. (21 citations)
- Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis. (21 citations)
- Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. (21 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Cytokine
- Internal medicine
Mariagrazia Uguccioni mainly focuses on Cancer research, Chemokine receptor, Signal transduction, Chemokine and Monocyte.
Mariagrazia Uguccioni has included themes like Cell migration, Cancer cell, Lidocaine and Calcium in biology, Receptor in his Cancer research study.
His research on Chemokine receptor frequently links to adjacent areas such as Synovial membrane.
His research integrates issues of Cancer and Breast cancer in his study of Signal transduction.
Mariagrazia Uguccioni is interested in CXCL13, which is a branch of Chemokine.
His Monocyte research includes themes of Inflammation, HMGB1, TLR2 and Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
